Loading clinical trials...
Loading clinical trials...
A Phase II Trial Evaluating APX005M (a CD40 Agonistic Monoclonal Antibody) in Combination With Standard-of-Care Doxorubicin for the Treatment of Advanced Sarcomas
Conditions
Interventions
Doxorubicin
APX005M
Locations
3
United States
City of Hope
Duarte, California, United States
Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri, United States
Columbia University Irving Medical Center/NYP
New York, New York, United States
Start Date
March 20, 2019
Primary Completion Date
December 31, 2026
Completion Date
December 31, 2026
Last Updated
April 29, 2025
NCT07156565
NCT02701153
NCT07432932
NCT07222735
NCT06500065
NCT06797999
Lead Sponsor
Alexander Z. Wei, MD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions